Department of Cell Biology, Biotechnology Research Institute, National Research Centre, Giza, Egypt.
Department of Parasitology and Animal Diseases, Veterinary Research Institute, National Research Centre, Giza, Egypt.
Vet Res Commun. 2024 Feb;48(1):245-257. doi: 10.1007/s11259-023-10207-w. Epub 2023 Aug 29.
Exposure to gamma rays from cobalt 60 (Co) can induce a complete inactivation of Mannheimia haemolytica. The inactivated bacterial pathogen is a potential vaccine candidate for immunization of ruminants such as sheep. The subcutaneous administration of irradiated vaccine in a two-dose regimen (4.0 × 10 colony forming unit (CFU) per dose) results in no mortality in any of the vaccinated sheep during immunization and after subsequent challenge of the live bacteria of the same strain of M. haemolytica. A significant rise in serum IgG titer, detected through ELISA, is observed after the passage of two weeks from the inoculation of the first dose whereas, the peak of the mean serum antibody titer occurred after two weeks of booster dose. The vaccination does not bring significant change to the IFN-γ levels in serum. The bacterial challenge of the vaccinated sheep does not induce a further seroconversion relative to serum antibody titer. In conclusion, the vaccinated sheep are protected by the elevated IgG titer and increased levels of IL-4 (Th-2 response) compared to the non-vaccinated sheep. Radiation technology can provide the opportunity for mass production of immunologically safe vaccines against animal and zoonotic diseases. Ethics Approval by the National Research Center Ethics Committee (Trial Registration Number (TRN) no 13,602,023, 13/5/2023) was obtained.
钴 60(Co)产生的伽马射线照射可完全使溶血曼海姆菌失活。这种经灭活的细菌病原体是一种有潜力的疫苗候选物,可用于免疫反刍动物,如绵羊。采用两剂皮下注射方案(每剂 4.0×10 个集落形成单位(CFU))对绵羊进行免疫接种,在免疫接种期间和随后用相同的溶血曼海姆菌菌株的活菌进行攻毒,没有任何接种绵羊死亡。在第一次接种后两周,通过 ELISA 检测到血清 IgG 滴度显著升高,而在加强剂量后两周,平均血清抗体滴度达到峰值。接种疫苗不会使血清 IFN-γ水平发生显著变化。与血清抗体滴度相比,对免疫接种绵羊进行细菌攻毒不会引起进一步的血清转化。总之,与未接种疫苗的绵羊相比,接种疫苗的绵羊通过升高的 IgG 滴度和增加的 IL-4 水平(Th2 反应)得到保护。辐射技术为大规模生产针对动物和人畜共患疾病的免疫安全疫苗提供了机会。已获得国家研究中心伦理委员会的批准(试验注册号(TRN)为 13,602,023,2023 年 5 月 13 日)。